P
DNA icon

Pfizer’s Ginkgo Bioworks DNA Stock Holding History

Pfizer’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30K Hold
2,928
– – 0.02% 16
2026
Q1 		$17.4K Hold
2,928
– – 0.01% 17
2025
Q4 		$24.3K Hold
2,928
– – 0.01% 17
2025
Q3 		$42.7K Hold
2,928
– – 0.01% 20
2025
Q2 		$32.9K Hold
2,928
– – 0.01% 20
2025
Q1 		$16.7K Hold
2,928
– – ﹤0.01% 21
2024
Q4 		$28.8K Buy
+2,928
New +$25.1K ﹤0.01% 22

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Pfizer's DNA Position: Q2 2026 in Review

Pfizer held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 2,928 shares worth $30K. The position accounts for 0.02% of the portfolio, ranked #16.

Pfizer first reported a position in DNA in Q4 2024 and has held it in 7 quarters since. The position peaked at $42.7K in Q3 2025. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Pfizer held 2,928 shares of Ginkgo Bioworks worth $30K as of Q2 2026.
  • Pfizer left its Ginkgo Bioworks share count unchanged in Q2 2026.
  • Ginkgo Bioworks made up 0.02% of Pfizer's portfolio in Q2 2026, its #16 holding.
  • Pfizer first reported a position in Ginkgo Bioworks in Q4 2024 and has held it in 7 quarters since.
  • Pfizer's Ginkgo Bioworks position peaked at $42.7K in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Pfizer's 13F filing for Q2 2026, filed 13 Aug 2026.